QWM
VRTX icon

Quaker Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Quaker Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.48K Sell
7
-43
-86% -$19.1K ﹤0.01% 382
2026
Q1 		$22.3K Buy
50
+2
+4% +$933 0.01% 242
2025
Q4 		$21.8K Buy
48
+1
+2% +$431 0.01% 247
2025
Q3 		$18.4K Sell
47
-1
-2% -$418 0.01% 240
2025
Q2 		$21.4K Buy
+48
New +$22.1K 0.01% 243

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Quaker Wealth Management's VRTX Position: Q2 2026 in Review

Quaker Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 86% in Q2 2026, selling an estimated $19.1K and leaving 7 shares worth $3.48K. The position accounts for ﹤0.01% of the portfolio, ranked #382.

Quaker Wealth Management first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $22.3K in Q1 2026. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Quaker Wealth Management held 7 shares of Vertex Pharmaceuticals worth $3.48K as of Q2 2026.
  • Quaker Wealth Management sold 43 Vertex Pharmaceuticals shares in Q2 2026, an estimated $19.1K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Quaker Wealth Management's portfolio in Q2 2026, its #382 holding.
  • Quaker Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Quaker Wealth Management's Vertex Pharmaceuticals position peaked at $22.3K in Q1 2026.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Quaker Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.